SAb Biotherapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
86
- Stock Symbol
-
SABS
- Investments
-
1
- Share Price
-
$2.81
- (As of Friday Closing)
SAb Biotherapeutics General Information
Description
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Contact Information
Website
www.sab.bioCorporate Office
- 777 West 41st Street
- Suite 401
- Miami Beach, FL 33140
- United States
Corporate Office
- 777 West 41st Street
- Suite 401
- Miami Beach, FL 33140
- United States
SAb Biotherapeutics Timeline
SAb Biotherapeutics Stock Performance
As of 20-Nov-2026, SAb Biotherapeutics’s stock price is $2.81. Its current market cap is $253M with 90.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.81 | $2.91 | $2.44 - $5.15 | $253M | 90.1M | 627K | -$1.35 |
SAb Biotherapeutics Financials Summary
As of 30-Sep-2026, SAb Biotherapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 190,927 | 73,356 | 9,137 | 65,653 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (82,223) | 15,164 | (30,280) | (38,718) |
| Net Income | (80,520) | 13,274 | (34,105) | (42,194) |
| Total Assets | 235,644 | 172,810 | 44,195 | 83,941 |
| Total Debt | 4,918 | 5,951 | 4,669 | 5,907 |
SAb Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SAb Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
SAb Biotherapeutics Comparisons
Industry
Financing
Details
SAb Biotherapeutics Competitors (55)
One of SAb Biotherapeutics’s 55 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA |
SAb Biotherapeutics Patents
SAb Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022104127-A1 | Ungulate-derived polyclonal immunoglobulin specific for egfr and uses thereof | Inactive | 13-Nov-2020 | ||
| WO-2022104152-A1 | Ungulate-derived polyclonal immunoglobulin specific for pd-l1 and uses thereof | Inactive | 13-Nov-2020 | ||
| US-11975066-B2 | Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof | Active | 31-Aug-2020 | ||
| US-20220062405-A1 | Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof | Active | 31-Aug-2020 | ||
| US-20240374704-A1 | Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof | Pending | 31-Aug-2020 | A61K39/12 |
SAb Biotherapeutics Signals
SAb Biotherapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SAb Biotherapeutics Acquisitions (1)
SAb Biotherapeutics’s most recent deal was a Merger/Acquisition with Big Cypress Acquisition for . The deal was made on 25-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Big Cypress Acquisition | 25-Oct-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
SAb Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
SAb Biotherapeutics FAQs
-
When was SAb Biotherapeutics founded?
SAb Biotherapeutics was founded in 2014.
-
Where is SAb Biotherapeutics headquartered?
SAb Biotherapeutics is headquartered in Miami Beach, FL.
-
What is the size of SAb Biotherapeutics?
SAb Biotherapeutics has 86 total employees.
-
What industry is SAb Biotherapeutics in?
SAb Biotherapeutics’s primary industry is Drug Discovery.
-
Is SAb Biotherapeutics a private or public company?
SAb Biotherapeutics is a Public company.
-
What is SAb Biotherapeutics’s stock symbol?
The ticker symbol for SAb Biotherapeutics is SABS.
-
What is the current stock price of SAb Biotherapeutics?
As of 20-Nov-2026 the stock price of SAb Biotherapeutics is $2.81.
-
What is the current market cap of SAb Biotherapeutics?
The current market capitalization of SAb Biotherapeutics is $253M.
-
Who are SAb Biotherapeutics’s competitors?
Ayala Pharmaceuticals, Inovio Pharmaceuticals, Marengo Therapeutics, Kite Pharma, and Intellia Therapeutics are some of the 55 competitors of SAb Biotherapeutics.
-
What is SAb Biotherapeutics’s annual earnings per share (EPS)?
SAb Biotherapeutics’s EPS for 12 months was -$1.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process